Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U A Matulonis

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 7, 2017
PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?U A Matulonis, B J Monk
American Journal of Hematology|April 1, 1994
Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalanU A Matulonis, J D Griffin, G P Canellos
Blood|May 1, 1995
Role of B7-1 in mediating an immune response to myeloid leukemia cellsU A Matulonis, C Dosiou, C Lamont, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 26, 2008
Long-term adjustment of early-stage ovarian cancer survivorsU A Matulonis, A Kornblith, H Lee, et al.
Gynecologic Oncology|August 7, 2004
Attitudes to chemotherapy in patients with ovarian cancerR T Penson, F Dignan, M V Seiden, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancerK A Havlin, M J Ramirez, C M Legler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 14, 2005
A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumorsR T Penson, S M Campos, M V Seiden, et al.
Gynecologic Oncology|March 29, 2006
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancerU A Matulonis, S Campos, L Duska, et al.
Gynecologic Oncology|May 2, 2001
The clinical utility of liposomal doxorubicin in recurrent ovarian cancerS M Campos, R T Penson, A R Mays, et al.
Gynecologic Oncology|June 30, 2006
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimenU A Matulonis, S Campos, C N Krasner, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 7, 2017
PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?U A Matulonis, B J Monk
American Journal of Hematology|April 1, 1994
Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalanU A Matulonis, J D Griffin, G P Canellos
Blood|May 1, 1995
Role of B7-1 in mediating an immune response to myeloid leukemia cellsU A Matulonis, C Dosiou, C Lamont, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 26, 2008
Long-term adjustment of early-stage ovarian cancer survivorsU A Matulonis, A Kornblith, H Lee, et al.
Gynecologic Oncology|August 7, 2004
Attitudes to chemotherapy in patients with ovarian cancerR T Penson, F Dignan, M V Seiden, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancerK A Havlin, M J Ramirez, C M Legler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 14, 2005
A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumorsR T Penson, S M Campos, M V Seiden, et al.
Gynecologic Oncology|March 29, 2006
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancerU A Matulonis, S Campos, L Duska, et al.
Gynecologic Oncology|May 2, 2001
The clinical utility of liposomal doxorubicin in recurrent ovarian cancerS M Campos, R T Penson, A R Mays, et al.
Gynecologic Oncology|June 30, 2006
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimenU A Matulonis, S Campos, C N Krasner, et al.
Pageof 3